Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962822 | 0.87 | ELANE (0.37) | ELANESMN1; SMN2MAPTNR2F2HTT | |
| SCHEMBL963132 | 0.86 | L3MBTL1 (0.48) | ELANESMN1; SMN2MAPTNR2F2HTT | |
| SCHEMBL963133 | 0.86 | L3MBTL1 (0.48) | ELANESMN1; SMN2MAPTNR2F2HTT | |
| SCHEMBL5126136 | 0.83 | ELANE (0.36) | ELANESMN1; SMN2MAPTNR2F2HTT | |
| SCHEMBL5126154 | 0.83 | ELANE (0.36) | ELANESMN1; SMN2MAPTNR2F2HTT | |
| SCHEMBL963252 | 0.79 | ELANE (0.39) | ELANESMN1; SMN2HTTL3MBTL1RORC | |
| SCHEMBL965294 | 0.79 | EGFR (0.41) | ELANESMN1; SMN2MAPTHTTALDH1A1 | |
| SCHEMBL965295 | 0.79 | EGFR (0.41) | ELANESMN1; SMN2MAPTHTTALDH1A1 | |
| SCHEMBL965833 | 0.78 | GLO1 (0.37) | ELANESMN1; SMN2MAPTNR2F2HTT | |
| SCHEMBL965832 | 0.78 | GLO1 (0.37) | ELANESMN1; SMN2MAPTNR2F2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | ELANE 2515/4885SMN1; SMN2 3745/4885MAPT 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.